2018 年第 1 期 第 13 卷

布地奈德联合孟鲁司特对支气管哮喘患儿炎性因子及免疫功能的影响

作者：施弦郁峰

英文作者：

单位：413000长沙，湖南省儿童医院呼吸一科（施弦）；313000浙江省湖州市中心医院儿科（郁峰）

英文单位：

关键词：支气管哮喘；布地奈德；孟鲁司特；炎性因子；T淋巴细胞亚群

英文关键词：

• 摘要：

• 【摘要】目的    探讨布地奈德联合孟鲁司特对支气管哮喘患儿炎性因子及免疫功能的影响。方法    选择2015年7月至2016年6月于我院诊治的支气管哮喘患儿96例为研究对象，根据随机数字表分为观察组和对照组，各48例。对照组给予布地奈德经口吸入治疗，观察组在对照组基础上联合孟鲁司特口服治疗，2组均治疗4个月。比较2组临床疗效及治疗前后血清炎性因子、T淋巴细胞亚群指标。结果    治疗4个月后，观察组总有效率明显高于对照组［93.7%(45/48)比79.2%(38/48)］，差异有统计学意义（χ2=4.360，P=0.015）。治疗4个月后，观察组血清白细胞介素6、肿瘤坏死因子α、高敏C反应蛋白、CD+4水平及CD+4/CD+8比值均明显低于对照组［（45±6）ng/L比（78±9）ng/L、（8.2±1.1）ng/L比（13.4±1.4）ng/L、（8.0±1.1）mg/L比（11.3±1.2）mg/L、（45±5）%比（48±6）%、（1.13±0.24）比（1.35±0.28）］，CD+3、CD+8水平明显高于对照组［（67±7）%比（63±7）%、（40±5）%比（36±4）%］，差异均有统计学意义（均P＜0.05）。结论    布地奈德联合孟鲁司特治疗有助于提高支气管哮喘患儿临床疗效，可能与缓解炎性反应、调节免疫功能有关。

• Effect of budesonide combined with montelukast on inflammatory factors and immune function in children with bronchial asthma

  Shi Xian, Yu Feng

  The First Department of Respiratory Medicine, Hunan Children′s Hospital, Changsha 413000, China(Shi X); Department of Paediatrics, Huzhou Central Hospital, Zhejiang Province, Huzhou 313000, China(Yu F)

  Corresponding author: Yu Feng, Email: youyuwind@163.com

  【Abstract】Objective     To investigate the effect of budesonide combined with montelukast on inflammatory factors and immune function in children with bronchial asthma. Methods    A total of 96 children with bronchial asthma were enrolled from July 2015 to June 2016 in our Hospital; they were randomly divided into observation group and control group, with 48 cases in each group. The control group had budesonide inhalation therapy; the observation group took montelukast on the basis of control group; both groups were treated for 4 months. Clinical efficacy, levels of serum inflammatory factors and T lymphocyte subsets were analyzed. Results    The total effective rate in observation group was significantly higher than that in control group［93.7%(45/48) vs 79.2%(38/48)］(χ2=4.360, P=0.015). After 4 months of treatment, levels of serum interleukin-6, tumor necrosis factor-α, high-sensitivity C-reactive protein, CD+4 and CD+4/CD+8 in observation group were significantly lower than those in control group［（45±6）ng/L vs （78±9）ng/L, （8.2±1.1）ng/L vs （13.4±1.4）ng/L, （8.0±1.1）mg/L vs （11.3±1.2）mg/L, （45±5）% vs （48±6）%, （1.13±0.24） vs （1.35±0.28）］; levels of CD+3 and CD+8 in observation group were significantly higher than those in control group［（67±7）% vs （63±7）%, （40±5）% vs （36±4）%］(P＜0.05). Conclusion    Budesonide combined with montelukast can help improve clinical efficacy of children with bronchial asthma, which may be related to alleviating inflammatory response and regulating immune function.

  【Key words】Bronchial asthma；Budesonide；Montelukast；Inflammatory factors；T lymphocyte subsets